Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
Launched by SALUDA MEDICAL PTY LTD · Dec 4, 2020
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to deliver treatment for chronic pain using a specialized device called the Evoke System. The trial aims to evaluate a closed-loop system that automatically adjusts the treatment based on the patient's needs, which could lead to better pain management. Researchers are looking for participants aged 65 to 74 who have either already received the Evoke System or are planning to get it. It's important that participants are able to give their consent and follow the study requirements.
If you decide to participate, you can expect to contribute to important research that may help improve pain management for many others. There are no specific exclusion criteria, so if you meet the age and device criteria, you might be eligible to join. This study is actively recruiting participants, and your involvement could play a key role in advancing treatments for chronic pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject has undergone trial implant or is planning to be implanted with the Evoke System within its approved indication.
- • 2. Subject is willing and capable of giving informed consent and able to comply with study-related requirements.
- Exclusion Criteria:
- • N/A
About Saluda Medical Pty Ltd
Saluda Medical Pty Ltd is a pioneering medical technology company focused on developing innovative neuromodulation therapies for the treatment of chronic pain and other neurological disorders. With a commitment to advancing patient care through cutting-edge research and development, Saluda Medical leverages its proprietary technology platform to create solutions that enhance the effectiveness and safety of treatments. The company's dedication to clinical excellence is reflected in its robust clinical trial programs, aimed at validating the efficacy and reliability of its therapies. Through collaboration with healthcare professionals and regulatory bodies, Saluda Medical strives to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Leonards, New South Wales, Australia
Broadmeadow, New South Wales, Australia
Garran, Australian Capital Territory, Australia
Bella Vista, New South Wales, Australia
Charlestown, New South Wales, Australia
Hurstville, New South Wales, Australia
Newtown, New South Wales, Australia
St Leonards, New South Wales, Australia
Sydney, New South Wales, Australia
Wahroonga, New South Wales, Australia
Fortitude Valley, Queensland, Australia
Noosa Heads, Queensland, Australia
Peregian Beach, Queensland, Australia
Wayville, South Australia, Australia
Clayton, Victoria, Australia
Frankston, Victoria, Australia
Geelong, Victoria, Australia
Richmond, Victoria, Australia
Richmond, Victoria, Australia
Cottesloe, Western Australia, Australia
Brisbane, Queensland, Australia
Auchenflower, Queensland, Australia
Brisbane, Queensland, Australia
Patients applied
Trial Officials
Angela M Leitner
Study Director
Saluda Medical Pty Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials